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Abstract
Introduction: The serotonergic neurotransmitter system is closely linked to depression and personality traits. It is not known
if selective serotonin reuptake inhibitors (SSRI) have an effect on neuroticism that is independent of their effect on
depression. Healthy individuals with a genetic liability for depression represent a group of particular interest when
investigating if intervention with SSRIs affects personality. The present trial is the first to test the hypothesis that
escitalopram may reduce neuroticism in healthy first-degree relatives of patients with major depressive disorder (MD).
Methods: The trial used a randomized, blinded, placebo-controlled parallel-group design. We examined the effect of four
weeks escitalopram 10 mg daily versus matching placebo on personality in 80 people who had a biological parent or sibling
with a history of MD. The outcome measure on personality traits was change in self-reported neuroticism scores on the
Revised Neuroticism-Extroversion-Openness-Personality Inventory (NEO-PI-R) and the Eysenck Personality Inventory (EPQ)
from entry until end of four weeks of intervention.
Results: When compared with placebo, escitalopram did not significantly affect self-reported NEO-PI-R and EPQ neuroticism
and extroversion, EPQ psychoticism, NEO-PI-R openness, or NEO-PI-R conscientiousness (p all above 0.05). However,
escitalopram increased NEO-PI-R agreeableness scores significantly compared with placebo (mean; SD) (2.38; 8.09) versus
(21.32; 7.94), p=0.046), but not following correction for multiplicity. A trend was shown for increased conscientiousness
(p=0.07). There was no significant effect on subclinical depressive symptoms (p=0.6).
Conclusion: In healthy first-degree relatives of patients with MD, there is no effect of escitalopram on neuroticism, but it is
possible that escitalopram may increase the personality traits of agreeableness and conscientiousness.
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Introduction
Neuroticism seems to reflect an enduring vulnerability to major
depressive disorder (MD) partly reflecting shared genetic risk factors
[1]. Most of the genetic risk for MD expressed via personality is
captured by neuroticism, with a modest influence of conscientious-
ness, and with small influence of openness, extroversion, and
agreeableness [2,3]. When neuroticism decreases in patients with
depression treated with antidepressants, it has been difficult to clearly
distinguish the treatment effect on neuroticism from the treatment
effect on the depressive disorder,as remission of depressive symptoms
is associated with partial normalization of neuroticism [4]. Decrease
in neuroticism scores during paroxetine treatment of patients with
MD, even after controlling for depression improvement, has been
observed in a large group of depressed patients [4]. Thus, it is possible
that response to selective serotonin re-uptake inhibitors (SSRIs) may
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31980be mediated at least partly via a decrease in neuroticism [4,5]. Higher
neuroticism is associated with higher thalamic serotonin binding [6].
Furthermore, a recent study from our group has suggested that
familial risk of depression and neuroticism interact in their relation to
t h ed e g r e eo fs p e c i f i cs e r o t o n i nt r a n s p o r t e rb i n d i n g[ 7 ]
Two randomized trials have investigated the effect of SSRI on
behavior and aspects of personality with some relation to
neuroticism in healthy participants without a family history of
MD. Knutson et al. found that four weeks intervention with
paroxetine 20 mg/day (n=26) versus placebo (n=25) significantly
increased social affiliation and decreased negative affect [8]. Tse et
al. found that two weeks intervention with citalopram 20 mg/day
(n=11) compared with placebo (n=9) resulted in a statistically
significant increase in self-directedness [9]. Results from these
trials suggest that SSRIs may affect aspects of personality even in
the absence of clinical depression. SSRIs do not seem to influence
mood in healthy individuals [10–13]. Results from a number of
studies, although not all [14], have suggested increased levels of
neuroticism in healthy first-degree relatives of patients with MD
compared to healthy individuals without a family history of MD
[15]. However, no trial has investigated the effect of SSRIs on
neuroticism and other personality dimensions in healthy individ-
uals with a family history of MD [16].
Thus, to examine the effect of escitalopram on neuroticism and
other aspects of personality, and excluding an effect on depression,
we recruited healthy first-degree relatives of patients with MD for
the AGENDA (Associations between Gene-polymorphisms, En-
dophenotypes for Depression and Antidepressive Intervention)
trial. The trial is the first to investigate the effect of a four week
self-administered daily escitalopram versus placebo on personality
traits, as measured with the Revised Neuroticism-Extroversion-
Openness-Personality Inventory (NEO-PI-R) and the Eysenck
Personality Inventory (EPQ), in healthy individuals . We tested the
hypothesis that intervention with escitalopram for a month
compared with placebo decreases symptoms of neuroticsm in
healthy first-degree relatives of patients with MD.
Materials and Methods
Study design and Ethics Statement
The AGENDA trial was investigator initiated and designed.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. It was conducted as a participant-, investigator-,
observer-, and data-analyst-blinded trial. During the trial the
participants received either escitalopram 10 mg/day or placebo
for a period of four weeks. The trial was conducted from July 2007
until July 2009 at the Department of Psychiatry, Rigshospitalet
(now Psychiatric Centre Copenhagen), Denmark as part of the
Centre for Pharmacogenomics, University of Copenhagen, Den-
mark. The trial was conducted and monitored in accordance with
the International Conference on Harmonization for Good Clinical
Practice guidelines and principles expressed in the Declaration of
Helsinki. The Local Ethics Committee (De Videnskabsetiske
Komite ´er for Københavns og Frederiksberg Kommuner, Køben-
havns Kommune) approved the trial: H-KF 307413.
An independent data monitoring and safety committee was
established to further ensure the safety of the participants, should
the need have occurred for early stopping. All participants gave
written informed consent. The detailed trial protocol was published
ahead of study completion and the changes in neuroticism scale
scores on the NEO-PI-R and the EPQ were pre-defined outcomes
[17]. Results on the primary outcome change in the area under the
curve for cortisol measurements during the combined dexameth-
asone-corticotropin releasing hormone test have been reported
elsewhere [18], thus neuroticism was a secondary outcome in
addition to cognition published in [19].
Probands and participants
The selection of diseased probands and healthy participants has
previously been described in details [17]. Probands were patients
with a diagnosis of MD from psychiatric hospital in- or out-patient
contact in Denmark who participated in ongoing studies at the
Department of Psychiatry, Rigshospitalet, Denmark. The pro-
band’s diagnoses were validated by face-to-face interviews
including the semi-structured interview Schedules for Clinical
Assessment in Neuropsychiatry (SCAN) by trained clinicians [20].
Probands were asked to permit a contact to their adult children
and/or siblings who were the eligible participants for the
AGENDA trial. The probands (n=466) gave written permission
to contact 359 first-degree relatives, who were the potential
participants in the trial. The participant flow is shown in Figure 1.
Individuals of either sex, aged 18–60 years with Danish ethnicity
(i.e., born in Denmark with Danish parents and European
grandparents) were eligible for the trial. Ethnicity was used to get
a genetically homogeneous sample. We excluded individuals with
somatic illnesses or a handicap that made participation in the trial
impossible while six individuals with stable, treated milder medical
conditions were included: hypertensio arterialis (three), pancreatitis
antea (one), hypothyroidism (one), and acne vulgaris (one).
Furthermore, we excluded individuals with a daily intake of drugs
interfering with corticosteroids or escitalopram (cipralex), including
birth controlpills oranykind ofcorticosteroids, and individuals who
were allergic to the study drug or placebo. Additionally, former
medical or psychological treatment for diseases in the affective or
schizophrenic spectrum and current abuse of alcohol or psychotro-
pic medication led to exclusion. Women who were trying to
conceive, or who were pregnant or breastfeeding were excluded.
Women were postmenopausal or in the lutheal phase of the
menstrual cycle at the time of randomization. Women taking birth
control pills were instructed to discontinue these six weeks prior to
entering the trial. Furthermore, all women were carefully instructed
to use double barrier birth control methods and pregnancy tests
were performed both before and after the intervention [17].
Trial procedures
Escitalopram and placebo tablets were identical in appearance,
color, smell, taste and solubility allowing for blinding of the
assignment to intervention or placebo. H. Lundbeck A/S provided
identically appearing blister packages containing escitalopram or
placebo. An independent pharmacist then packed, sealed, and
numbered the drug packages according to a randomization list
provided and concealed by the Copenhagen Trial Unit (CTU). The
participants were randomized to self-administer a single dose of
either escitalopram 10 mg or placebo each evening for four weeks.
On completion of four weeks of double-blind intervention
participants entered a five-day blinded down-titration period to nil
medication.Adherenceto theprotocol wassought bymakingweekly
telephone calls to the enrolled participants. Following four weeks of
intervention the participants were asked, how adherent they had
been to the protocol, and if they had missed taking any tablets.
The sample size was estimated according to the primary
outcome as previously described [17]. The CTU conducted the
centralized computerized randomization by telephone to secure
adequate allocation sequence generation and allocation conceal-
ment [21]. Randomization was stratified in blocks by age (18–31
years and 32–60 years) and sex. Only the data manager knew the
block size, which was six. Participants were randomized 1:1 to
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done immediately after a face-to-face interview including the
SCAN-interview at the first scheduled appointment at the clinic
establishing that a participant fulfilled all the inclusion criteria and
none of the exclusion criteria. All trial personnel and participants
were blinded to the packaging of the study drug, and blinding was
maintained throughout monitoring, follow-up, data management,
assessment of outcomes, data analyses, and drawing of conclu-
sions. Then the randomization code was broken. The blinding was
successful as previously described [18].
Assessments
The first part of the assessment was a telephone interview, and
eligible individuals were scheduled to meet at the clinic on two
different days both before and following the four weeks of
intervention. On the first day of examination the participants gave
written informed consent after details of the trial were explained.
We did a SCAN interview (UK) and individuals with a prior or
current psychiatric diagnosis were excluded (n=59, see Figure 1).
Further assessment included information on family history of
psychiatric disorders, ratings of mood using the 17-item Hamilton
Depression Rating Scale (HAM-D) [22], and the 14-item Hamilton
Anxiety Scale [22], self-rated depressive symptoms by Beck
Depression Inventory, 42-items [23], various socio-demographics,
height,weight,routine bloodtests,and,apregnancytestforwomen.
Furthermore, blood was drawn for measurements of plasma
escitalopram, and the UKU Side Effect Rating Scale [24], was
appliedbytheprincipalinvestigatorafterfourweeksofintervention.
Figure 1. Flowchart consort for Agenda Trial Neuroticism.
doi:10.1371/journal.pone.0031980.g001
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The personality dimension neuroticism was assessed by the
Danish version of Eysenck Personality Questionnaire (EPQ)
[25,26], and the Revised Neuroticism-Extroversion-Openness-
Personality Inventory (NEO-PI-R) [27]. The EPQ comprises 101
yes-no items that measure the broad dimensions of neuroticism,
extroversion, and psychoticism. NEO-PI-R is a 240-items
inventory that evaluates the broad personality dimension of
neuroticism, extraversion, openness, agreeableness, and conscien-
tiousness. The score on each of the five broad dimensions was
derived by adding the scores from the assessments of six
constituent personality traits (facets). The respondent answers the
statements on a 5-point Likert scale from ‘disagree very much’ to
‘agree very much’. Both EPQ and NEO-PI-R were applied before
(entry) and following four weeks of intervention (4 weeks).
Measure of plasma escitalopram
Escitalopram was extracted and quantitated was carried out on
an ASPEC XL combined with a HPLC system, both from Gilson,
Villiers le Bell, France. Lower and upper limits of quantitation
were 10 and 3,600 nmol/l, respectively. Imprecision ranged from
5.5% to 8.4% and trueness ranged from 93.2% to 103.0% within
the measurement range. Extraction recovery was 38% and carry-
over was less than 1%.
Statistical methods
The data analyses planned for the secondary outcomes were
described in a pre-established statistical analysis plan [17]. The
null-hypotheses to be tested were that there would be no difference
between the two intervention arms with regard to changes in
neuroticism assessed by the EPQ and NEO-PI-R. The outcomes
were changes in personality scores calculated as the score at week
4 minus the score at entry for the individual participants. Firstly,
independent samples t-tests were used to compare change scores in
the escitalopram and placebo groups for NEO-PI-R neuroticism
and EPQ neuroticism. Secondly, adjustments were planned to be
conducted for age, sex, years of education, and concentration of
escitalopram in plasma in a general linear model if these variables
were associated with change in neuroticism at the 0.1 level of
significance [17].
Results
A total of 80 participants were randomized. The characteristics
of the participants can be seen in Table 1. The mean age of non-
participants was 37 (SD11) years and 58% were women. The
reasons for non-participation are presented in Figure 1. A
statistically significant correlation was found between EPQ
neuroticism and NEO-PI-R neuroticism reported at entry
(Pearsson=0.8; p,0.0005). There was no statistical significant
difference in the change of HAM-D (four weeks - entry) between
the escitalopram group and the placebo group (p=0.6). No severe
adverse reactions or serious adverse events were obseved. The side
effect measure UKU total for participants of the escitalopram and
placebo groups did not differ significantly at four weeks (Table 1).
However, sexual adverse effects showed a statistically significant
increase and insomnia showed a statistically significant decrease in
the escitalopram group compared with the placebo group [18].
Effects on neuroticism
The dataset was complete with the exception of one man and
one woman in the escitalopram group, who left the trial prior to
the intervention, and two men in the placebo group in whom data
collection failed for both EPQ and NEO-PI-R in one and for EPQ
in another, see Figure 1. There was no statistical significant
difference in the change in reported neuroticism scores according
to the NEO-PI-R (p=0.09) and the EPQ (p=0.7) for participants
who got escitalopram compared to those who got placebo
(Table 2). No stastistically significant correlations were found
between change in neuroticism measured using EPQ or NEO-PI-
R, and age, sex, years of education, or plasma escitalopram. The
exclusion of two participants with immeasurable concentrations
did not change the results substantially.
Further analyses showed no statistically significant correlations
between: change in EPQ neuroticism and BDI-21 at entry
(rho=20.26; p=0.06), change in EPQ neuroticism and HAM-D
at entry (rho=0.12; p=0.3), change in NEO-PI-R neuroticism
and BDI-21 at entry (rho=20.10; p=0.4), and change in NEO-
PI-R neuroticism and HAM-D at entry (rho=20.05; p=0.7).
Furthermore, no statistically significant differences were shown
in changes in EPQ extraversion (p=0.2), EPQ psychoticism
(p=1.0), NEO-PI-R extraversion (p=0.9), NEO-PI-R openness
(p=0.3), and NEO-PI-R conscientiousness (p=0.07) between
escitalopram and placebo participants. However, a statistically
significant difference was found in the change in NEO-PI-R
agreeableness between escitalopram (mean: 2.38, SD; 8.09) and
placebo (mean 21.32, SD: 7.94; p=0.046 (Table 2).
Discussion
The results of the AGENDA trial do not support our hypothesis
that a four-week long intervention with escitalopram as compared
with placebo would decrease EPQ or NEO-PI-R neuroticism total
scores in healthy first-degree relatives of patients with MD.
However, we found statistically significant changes on the
agreeableness dimension of personality on the NEO-PI-R,
(p=0.046) but none of the other dimensions of personality
measured by EPQ or NEO-PI-R were significantly affected by the
intervention. We found a trend for change in NEO-PI-R
conscientiousness (p=0.07) between escitalopram and placebo
participants. We had no hypothesis regarding conscientiousness,
and greater statistical power might have been needed to evaluate
this item. We found no significant correlation between change in
neuroticism during intervention, and age, sex, education or plasma
escitalopram concentration, respectively.
Our present trial is the first to suggest an effect of escitalopram
on agreeableness in healthy individuals without depressive
symptoms. The trial has several advantages. The participants
were studied in a randomized clinical trial blinded in all phases
including the statistical analyses and conclusion phase. The trial
and the analyses were carried out as planned in advance and the
completion and compliance in the trial was very high. The
registered diagnosis of depression for the probands was verified by
a face-to-face psychiatric research interview by trained medical
doctors. The participants were assessed and diagnosed by
validated and frequently used multi-dimensional methods. Fur-
ther, the participants were subjected to four weeks of intervention
thus including the interval in which clinical improvement has been
reported in trials with patients with MD [28]. Personality variables
were assessed with the NEO-PI-R and EPQ, both widely used self-
report measures based on the Five-Factor Model of Personality
[29].
Despite these advantages our trial also has a number of potential
limitations. Firstly, a large number of women were excluded from
our trial due to oral contraceptives and pregnancy, thus the trial
population is characterized by an overrepresentation of men.
Secondly, we cannot exclude that the dosage of 10 mg
escitalopram was too low although this has been suggested as
Effect of Escitalopram on Personality Traits
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Even though the participants received weekly phone calls to
optimise adherence, several of the participants in the escitalopram
group were found to have low plasma escitalopram concentra-
tions. We considered using a higher dosage, but escitalopram
20 mg daily might have given more adverse effects, eventually
jeopardizing blinding and adherence, thus we decided to use
10 mg daily. This dose of escitalopram resulted in well-known
adverse effects, such as sexual adverse effects, as described in a
prior paper from the study [18]. Further, the exclusion of the two
participants with immeasurable concentrations did not change the
results substantially. Thirdly, it may be argued that four weeks of
treatment is too short a period to affect aspects of personality.
However, two prior studies on the effect of SSRI on personality
revealed positive effects within a four week [8] and a two week [9]
treatment period, respectively. Thus, these trials reported changes
in relatively complex tasks or in specific measures (hostility,
submissiveness) rather than the broad personality self-report
descriptors as the NEO-PI or EPQ. Instead neuroticism was
found to be affected after 8 weeks of administration by Tang et al.
2009. Moreover, we have not compared healthy individuals with a
family history of MDD to healthy individuals without a family
history of MD. Finally considering the multitude of statistical
significance tests performed a p value of 0.046 may very well occur
by chance and correction for multiple testing would render it
insignificant. It should be noted that when adjusting for multiple
analyses the p value for agreeableness was p=0.28 using Holm’s
test. Thus the result needs to be confirmed in additional studies.
We planned to include 80 participants due to resources and
availability of the healthy first-degree relatives of patients with MD,
as previously described [17] and the AGENDA trial is the largest
trial (n=80) on healthyregarding any outcome, as shown ina recent
review from our group [16]. We found a tendency for escitalopram
to reduce neuroticism when measured by the NEO-PI-R, but the
opposite tendency when neuroticism was measured by the EPQ.
Thus, it may not seem likely that our results are due to type II errors
and that a larger sample would have changed the results.
Furthermore, neuroticism reported by EPQ and NEO-PI-R was
closely correlated. It was not validated that the probands and the
participants of the trial were indeed related. Furthermore, while our
Table 1. Clinical and demographic characteristics of participants in the Agenda Trial.
Characteristic
Escitalopram
(n=41)
Placebo
(n=39)
All Participants
(n=80)
Age – yr, mean 6 SD 32611 31611 32610
Women – N (%) 15 (37) 14 (36) 29 (36)
Education – mean 6 SD
Years of school 11611 1 611 1 61
Years of further education 3623 623 62
First degree relatives of patient with a history of major depressive disorder
– median (25,75 quartiles)
1 (1;2) 1 (1;2) 1 (1;2)
17-item Hamilton Depression Scale Score – median (quartiles) (range) 1 (0;3)
(0–7)
1 (0;3)
(0–7)
1 (0;3)
(0–7)
Beck Depression Inventory, 21-item, depression – median (25,75 quartiles) 2 (0;4) 2 (0;3) 2 (0;5)
Side Effects UKU total score (4 weeks), median (25,75 quartiles), (range) 1
(0–4), (0–13)
0
(0–2), (0–7)
0
(0–3), (0–13)
Plasma escitalopram (4 weeks), nmol/l, 50629
- mean 6 SD, median (range) 48 (,10–138) ,10
Eysenck (entry)
- mean 6 SD, median (25,75 quartiles)
6.865.3 7.364.4 7.064.8
Neuroticism 7 (1.5;10) 6.0 (4;10) 6.5 (3;10)
16.063.8 14.764.5 15.464.2
Extraversion 17 (14.5; 18.5) 17 (12;18) 17 (14;18)
NEO-PI-R (entry)
- mean 6 SD, median (25,75 quartiles)
68624 71618 70621
Neuroticism 66 (50;85) 70 (59–85) 68 (55;85)
125619 123616 124618
Extraversion 123 (110;138) 125 (111;136) 123 (110;136)
114617 118618 116674
Openness 114 (99;125) 120 (106;131) 115 (100;130)
124618 128612 126654
Agreeableness 125 (118;136) 128 (119;138) 127 (118;137)
114620 113617 114618
Conscientiousness 115 (104;133) 111 (102;124) 112 (102;126)
doi:10.1371/journal.pone.0031980.t001
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develop depression and thepossible effectwefound onagreeableness
and conscientiousness may not be related to depression.
Results from a recent placebo-controlled trial in patients with
major depression suggest that the SSRI paroxetine has a specific
effect on personality traits of neuroticism and extraversion that is
distinct from its effect on depression [4]. In a randomised
controlled trial of patients with depression, neurotiscism and
conscientiousness were significantly associated with response to a
combination of medication and psychoterapy [31]. Our results
suggest that escitalopram has no major direct effect on
neuroticism, i.e., independently of the effect of depressive
symptoms. We have chosen to recruit a sample of individuals
with positive family history for MD, based on previous reports of
increased neuroticism in this population. However, based on the
mean scores reported in Table 1, the study sample presents with
low-medium neuroticism levels thus breaking the original study
design assumption. In fact, none of the subjects seem to report
levels of neuroticism that would be considered as high and thus
represent a risk factor for psychopathology. As familiarity for MD
and neuroticism are likely to present both shared and non-shared
contributions to higher vulnerability, it remains open for
speculation whether a sample with positive family history but
low-medium neuroticism scores (as in this trial) could in fact
present some resilience towards the development of depression
and perhaps a different response to antidepressants. This could
also account for the negative results reported of 4 weeks
antidepressant medication not affecting neuroticism levels. It
could be hypothesised that changes in neuroticism by antidepres-
sant medication only occur in the presence of baseline high
neuroticism (as in a paper by Tang et al., 2009 [4]). This would be
also supported by recent data showing that 1 week of
antidepressant administration is able to modify negative biases in
emotional processing correlated to high neuroticism [32].
According to the cognitive neuropsychological model of antide-
pressant drug action [33], antidepressants may work by modifying
emotion processing biases and thus in turn producing changes at a
phenotypic level such as symptoms and possibly personality
measures.
Agreeableness isless studied in relation todepression. Ina study of
depressed patients (n=53) [34] agreeableness was not significantly
affected by SSRI treatment by flouoxetine. However, a study by
Eskelius et al. found small but statistically significant changes in all
the Karolinska Scales of Personality except the impulsiveness scale
after24weeksoftreatmentwithsertralineorcitalopramindepressed
patients. The changes (2.3–12.4%) were in the direction of
normalisation, i.e., decreases in the anxiety and aggression-related
scales and increases in social desirability and socialisation [35].
Studies of healthy first-degree relatives offer an excellent
opportunity to determine whether personality traits represent a
premorbid risk factor for subsequent onset of mood disorders or
whether personality deviances are a consequence of mood episodes
[15]. Future studies may explore the suggested link between the
serotonergic system and the personality trait agreeableness. If the
finding of changes in agreeableness is replicated, it may lead to the
hypothesis that SSRI do not directly modulate neuroticism but
rather mediate a different self-perception captured by changes in
the scores of the facets of the personality dimension of
agreeableness, which are trust, straightforwardness, altruism,
compliance, modesty, and tender mindedness. Further it could
be hypothesized that antidepressants first produce early changes in
personality dimensions related to interpersonal measures in the
direction of more positive interactions and that longer treatment is
needed to affect self-reported measures of negative emotionality.
In conclusion, the AGENDA trial is the first trial to investigate if
treatment with a SSRI has an effect on personality traits in healthy
first-degree relatives of patients with major depressive disorder. No
significant changes were found on any measure of neuroticism. In
post-hoc analyses, escitalopram seemed to have an effect on
agreeableness. Further, a trend was found for increased conscien-
tiousness. Thus it is possible that SSRIs may have an effect on
aspects of personality such as agreeableness and conscientiousness
independent of the treatment effect on depression. The finding
should be explored in future studies.
Table 2. Changes in personality scores in the escitalopram and the placebo group following four weeks of treatment.
Personality trait
(4 weeks -entry)
Intervention
group Mean (SD) Median
Minimum
value
Maximum
value
Inter
quartile range p
Neuroticism
c Escitalopram 21.77 (3.74) 21 291 2 4
Placebo 22.08 (2.86) 22 29 4 4 0.73
b
Neuroticism
d Escitalopram 23.01 (10.3) 24 231 19 10
Placebo 1.00 (10.5) 1 221 27 16 0.09
a
Extraversion
d Escitalopram 1.51 (7.95) 2 216 18 10 0.90
a
Placebo 1.32 (6.24) 2 215 15 8
Openness
d Escitalopram 3.18 (9.84) 5 230 20 8 0.33
b
Placebo 2.15 (9.97) 3 217 38 14
Agreeableness
d Escitalopram 2.38 (8.09) 1 218 19 11 0.046
a
Placebo 21.32 (7.94) 23 215 18 11
Conscientiousness
d Escitalopram 1.85 (8.41) 2 212 20 14 0.07
a
Placebo 22.34 (11.4) 21 242 14 14
a) The distributions did not differ significantly from the normal distribution (Shapiro Wilkes test) and a t-test was used to compare the escitalopram and the placebo arm.
P of Levene’s test ranged from 0.11 to 0.80.
b) The distributions differed from the normal distribution but judged from the graphical displays (histograms and probability distributions) they followed normal
distributions with reasonable approximation, thus a t-test was also used.
c) Eysenck: Escitalopram (n=39), placebo (n=37).
d) NEO-PI-R: Escitalopram (n=39), placebo (n=38).
doi:10.1371/journal.pone.0031980.t002
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